Sign in
Taking people in United StatesNo phase

Testing semaglutide with or without exercise in people with obesity

Tests semaglutide and exercise on muscle and body function in adults with obesity.

Key facts

Who runs it
Washington University School of Medicine
Where
St Louis, United StatesSee the site
Trial code
Registry title
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Status
Recruiting
People taking part
40 people, planned
Started
11 Aug 2025
Expected to end
1 Aug 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Exercise training
  • Semaglutide
  • Therapy Cessation
Record updated
10 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50 to 75 with obesity and reduced physical function. It studies semaglutide with or without exercise, and what happens after stopping.

Age
50 to 75 years
Sex
Men and women
Disease stage
Obesity (body mass index of 30 kg/m2 or more) and decreased physical function (Modified Physical Performance Test score 17 to 31).
Earlier treatment
People who take a GLP-1 or other weight loss medication, or who have had bariatric surgery, cannot join. People planning endoscopic or bariatric surgery for obesity also cannot join.

Main reasons for not taking part

  • Diabetes
  • Unstable weight (more than 4% change in the last 2 months)
  • 150 minutes or more per week of structured exercise
  • Significant heart or lung disease, or kidney problems (eGFR below 30 mL/min/1.73 m2)
  • History of pancreatitis, or pregnant or breast-feeding women

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • i) obesity (Body Mass Index ≥ 30 kg/m2)
  • ii) decreased physical function (Modified Physical Performance Test score 17 to 31)
  • iii) approval of their primary physician to participate in this study

Who cannot take part

  • i) unstable weight (>4% change during the last 2 months before entering the study)
  • v) therapy with a GLP-1 or other weight loss medications
  • vi) clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal motility
  • viii) thyroid-stimulating hormone (TSH) >1.5X the upper limit of normal (patients receiving treatment for hypothyroidism may be included provided their thyroid hormone replacement dose has been stable for at least 3 months)
  • xiii) tobacco use, excessive alcohol intake (≥3 drinks/day for men and ≥2 drinks/day for women) or active substance abuse with illegal drugs by self-report, or regular marijuana use within 3 months of enrollment and unwilling to abstain from marijuana during the trial
  • xiv) Use of medications that are known to affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued for this study
  • xv) have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity
  • iii) diabetes
  • vii) history of chronic or acute pancreatitis
  • ix) history of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 months that would interfere with study participation
  • x) acute or chronic hepatitis, or other liver disease other than Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
  • xi) family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • xii) history of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
  • xvii) Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)
  • xii) history of seizure disorder
  • xx) allergy or hypersensitivity to GLP-1 RA medications
  • iv) significant cardiopulmonary disease (heart failure, angina, uncontrolled hypertension, chronic obstructive pulmonary disease) or other organ dysfunction (e.g., renal insufficiency [eGFR <30 mL/min/1.73 m2])
  • xvi) anemia (Hgb <10 g/dL)
  • ii) ≥150 min per week of structured exercise (e.g., jogging, activities that cause heavy breathing and sweating)
  • xix) Female who is pregnant, breast-feeding or intends to become pregnant
  • xxi) unable to grant voluntary informed consent
  • xxii) unable or unwilling to follow the study protocol or who, for any reason, the research team considers the participant is not an appropriate candidate for the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 50 and 75 years old?

Where in United States

  • Washington University School of MedicineSt Louis, United StatesContact: CoordinatorTaking people

About the trial

What the trial wants to find out

The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied.

Read full original descriptionShow less

In this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle, physical and metabolic function, muscle strength and appetite control and reward signaling in the brain in response to 1-year of GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle and appetite-related outcomes assessed 1-year after stopping treatment.

The 2 groups in the trial

  • GLP-1 RAExisting treatment, for comparison

    Participants in this group will receive semaglutide therapy along with diet behavior counseling for 52 weeks

    Treatment: Semaglutide and Therapy Cessation

  • GLP-1 RA + ExerciseTreatment being tested

    Participants in this group will receive semaglutide therapy along with diet behavior counseling and exercise training for 52 weeks.

    Treatment: Exercise training, Semaglutide, and Therapy Cessation

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With Obesity
Plain-language title
Testing semaglutide with or without exercise in people with obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07091500, who can take part
Record updated
10 July 2026